Said Mr. Holubiak, "The decades of scientific research into regenerative medicine is now showing dramatic results and fulfilling the promise we all had hoped for.
"Dr. Victor's pioneering efforts in the advancement of the science and his innovations in the use of ultrasonic cavitation is now setting the standard for the harvest of autologous stromal vascular fractions that are demonstrating promise in clinical efficacy.
"I am pleased to join the board of IntelliCell. The company is committed to far reaching clinical research in the treatment of osteoarthritis, diabetic ulcers, bone and dermal conditions where regenerative processes are desperately needed.
"I look forward to participating in the growth of IntelliCell at such an exciting time."
PROFILE: Myron Holubiak, new president of Roche Labs
by Camilla Huk
NUTLEY, N.J. - There was only one regret I had in meeting with the new president of Roche Labs, Myron Holubiak, and that was that his parents didn't live to see this accomplished man in his plush offices in the executive suite on the pharmaceutical giant's Nutley campus.
Roche Labs, a subsidiary of Hoffmann La Roche, has revenues of over $2.8 billion and 3,500 employees. It is a long way from the tent in the displaced persons camp in Linz, Austria, where Mr. Holubiak was born in 1947.
Like many Ukrainian families, Myron's father, Alexander, who was the mayor of Horozhanka in the Ternopil region, fled the terrors of the Soviet occupation. He eventually came to the United States with his wife, Stephanie, and three children, Myron, and his sisters, Vera (who had polio and was fully paralyzed) and Ivanka. Having survived incarceration
Check this out..MERCK subsidiary Millipore collaborating with Intellicell Biosciences..Millipore(American Subsidiary of MERCK)has executed an exclusive supply and sale agreement with IntelliCell BioSciences to sell and distribute the guava flow cytometry platform into the area of SVF..
Quote:Another extremely important piece of information brought out in Gene Marcial’s Forbes article is that Millipore, the American-based subsidiary of the large pharmaceutical company, Merck AG of Germany, has studied IntelliCell’s technology and “confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its competitor companies – that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.
Subsequently, Marketwire reported that Millipore Corporation “a global leader in innovative tools and technologies for bio-manufacturing and life science research, has executed an exclusive supply and sale agreement with IntelliCell BioSciences to sell and distribute the guava flow cytometry platform into the area of SVF. This collaboration will streamline the development of IntelliCell’s tissue processing centers in the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.”
Said Dr. Steven Victor, Founder and CEO of IntelliCell, “This is a phenomenal step in the right direction for our company, and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to sell their cutting-edge guava flow cytometer, combined with our proprietary process, which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for